Product
Double-Blind 0.1mg CBP-307
1 clinical trial
1 indication
Indication
Ulcerative ColitisClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)Status: Completed, Estimated PCD: 2022-02-23